R&D channel feed

An­oth­er biotech grabs the axe, chop­ping R&D in a ma­jor re­or­ga­ni­za­tion as drug sales dis­ap­point

3 years ago
People
Pharma

No­var­tis, BeiGene lay out front­line PhI­II da­ta for PD-1 drug as sec­ond-line PDU­FA date looms

3 years ago
China
Pharma

Plot­ting a come­back af­ter 2016 flop, Seres to raise $100M to prep C. dif­fi­cile pro­gram for launch

3 years ago
Financing

FDA side­lines Paul Hud­son's $3.7B MS drug af­ter es­tab­lish­ing link to liv­er dam­age

3 years ago
FDA+

An­gion, still reel­ing from past de­feats, scraps a PhII kid­ney dis­ease study af­ter 'un­ex­pect­ed' safe­ty event

3 years ago

Catch­ing up with Bris­tol My­ers and Mer­ck, As­traZeneca de­clares neoad­ju­vant win for PD-L1/chemo com­bo

3 years ago

No­vo Nordisk spells out the de­tails be­hind a PhII NASH fail­ure which re­shaped its clin­i­cal plans

3 years ago

Fac­ing set­backs for months and an ac­tivist at­tack, Cat­a­lyst Bio­sciences pre­pares to call it quits

3 years ago

San­ther­a's clin­i­cal da­ta are in, but NDA de­layed 4-6 months by third par­ty man­u­fac­tur­er

3 years ago

With da­ta to pro­pel it in­to PhI­II, 89bio asks mar­ket for near­ly $100M to bankroll ex-Te­va drug

3 years ago
Financing

Con­struc­tion un­der­way for new life sci­ence cen­ter to ac­com­mo­date Seat­tle's grow­ing life sci­ence sec­tor

3 years ago

Astel­las sub­sidiary to part­ner with Pitts­burgh up­start in search for 'un­drug­gable' pro­teins

3 years ago
Deals

Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

3 years ago

Basilea toss­es an on­col­o­gy drug back to Mer­ck, dou­bling down on an­tibi­otics in re­vamp

3 years ago
Deals

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

3 years ago

Jazz re­ports sur­prise PhI­II flop for cannabi­noid drug from $7.2B GW buy­out

3 years ago

Four months af­ter CRL due to con­t­a­m­i­nant wor­ries, Gilead re­turns to FDA for next-gen HIV drug

3 years ago
Pharma

Scoop: Roche scraps one of two schiz­o­phre­nia PhII tri­als af­ter fail­ing the pri­ma­ry end­point

3 years ago
Pharma

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

3 years ago

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

3 years ago

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

3 years ago

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

3 years ago

FDA places par­tial clin­i­cal hold on David Hung biotech af­ter cer­tain can­cer pa­tients ex­pe­ri­ence eye in­flam­ma­tion

3 years ago
FDA+

Re­lay builds out case for an­ti-FGFR drug, shoot­ing for first ac­cel­er­at­ed ap­proval on 'mo­tion-based' drug dis­cov­ery plat­form

3 years ago
First page Previous page 129130131132133134135 Next page Last page
A service from the Financial Times